Device Trial Radar · NCT07091682
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 18, 2025
Primary completion
Jun 2027
Study completion Jun 2031
Sponsor
- Lead sponsor
- Biotronik AGNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 29, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study objective is the assessment of safety and clinical performance of Freesolve 35- and 40-mm in de novo coronary artery lesions up to 38 mm length.
Conditions
- Coronary Artery Disease
- Atherosclerosis of Coronary Artery
- Myocardial Ischemia
- Ischemic Heart Disease
- Acute Coronary Syndromes
- Angina Pectoris
Interventions
Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium ScaffoldDevice
Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Target Lesion Failure (TLF) at 12 Months Post-Index ProcedureTime frame: 12 Months
Locations
14 sites in 7 countries. Site status is shown where the registry gives one.
Katholisches Krankenhaus "St. Johann Nepomuk"
Erfurt, Germany
Universitätsklinikum Halle (Saale)
Halle, Germany
Klinikverbund Allgäu gGmbH
Immenstadt and Kempten, Germany
11 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.